Everything below concerns immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
=== Gynecological cancers === Estradiol has been tied to the development and progression of cancers such as breast cancer, ovarian cancer and endometrial cancer. Estradiol affects target tissues mainly by interacting with two nuclear receptors called estrogen receptor α (ERα) and estrogen receptor β (ERβ). One of the functions of these estrogen receptors is the modulation of gene expression. Once estradiol binds to the ERs, the receptor complexes then bind to specific DNA sequences, possibly causing damage to the DNA and an increase in cell division and DNA replication. Eukaryotic cells respond to damaged DNA by stimulating or impairing G1, S, or G2 phases of the cell cycle to initiate DNA repair. As a result, cellular transformation and cancer cell proliferation occurs.
Traffic is heavy worldwide, with the biggest producer being Afghanistan. According to a U.N. sponsored survey, in 2004, Afghanistan accounted for production of 87 percent of the world's diamorphine. Afghan opium kills around 100,000 people annually. In 2003 The Independent reported:
RNAP initiates transcription of the trp promoter. RNAP pauses at about nucleotide 90 at a secondary structure (?the first one shown above?). Ribosomes engage this nascent mRNA and initiate translation of the leader peptide. RNAP is then "released" from its pause and continues transcription. When RNAP reaches the region of the potential terminator, whether it continues or not is dependent on the position of the ribosome "trailing behind". If the ribosome stalls at the tandem Trp codons, waiting for the appropriate tRNA, region 1 is sequestered within the ribosome and thus cannot base pair with region 2. This means that region 2 and 3 become based paired before region 4 can be transcribed. This forces region 4 when it is made to be single stranded, preventing the formation of the region 3/4 terminator structure. Transcription will then continue. If the ribosome translates the leader peptide with no hesitation, it then covers a portion of region 2 preventing it from base pairing with region 3. Then when region 4 is transcribed, it forms a stem and loop with region 3 and transcription is terminated, generating a ca. 140 base transcript. This mechanism of control measures the amount of available, charged Trp-tRNA. The location of ribosomes determines which alternate secondary structures form.
=== Chemical synthesis === The commercial production of amino acids usually relies on mutant bacteria that overproduce individual amino acids using glucose as a carbon source. Some amino acids are produced by enzymatic conversions of synthetic intermediates. 2-Aminothiazoline-4-carboxylic acid is an intermediate in one industrial synthesis of L-cysteine for example. Aspartic acid is produced by the addition of ammonia to fumarate using a lyase.
As a result, it is often combined with these drugs to reduce their side-effect profile and to produce a stronger antidepressant effect. Mirtazapine does not have pro-serotonergic activity and thus does not cause serotonin syndrome. This is in accordance with the fact that it is not a serotonin reuptake inhibitor or monoamine oxidase inhibitor, nor a serotonin receptor agonist. There are no reports of serotonin syndrome in association with mirtazapine alone, and mirtazapine has not been found to cause serotonin syndrome in overdose. However, there are a handful of case reports of serotonin syndrome occurring with mirtazapine in combination with serotonergic drugs like selective serotonin reuptake inhibitors, although such reports are very rare, and do not necessarily implicate mirtazapine as causative.
Sources: en.wikipedia.org
==== Tax deduction for qualified tip income ==== The law creates new tax deductions for tips of up to $25,000 per year received by workers earning less than $150,000, with the tax deduction set to expire in 2028. In order to be eligible, a tip must be paid voluntarily by the payor, and the payor must determine the amount of the tip. The payor must not be subject to a penalty if they do not pay a tip, and the tips must not be subject to any negotiation. The tip must be given to workers working one of 68 different job types. Tips received while performing a service that is a felony or misdemeanor are not eligible. Tips received for prostitution or pornography are not eligible. Tips received as part of a tip pool are generally eligible. Tips received directly by a supervisor or manager are eligible only if they are for services they provided in a qualified occupation and not as part of a tip pool. If the customer is charged a service charge or an automatic tip amount that is not voluntary on the part of the customer, then the service charge or tip is not eligible. This includes if the company requires a customer to pay a service charge or a particular tip amount on parties greater than a certain size. Voluntary tips above such a minimum or mandatory charge are eligible. Recommended tips are eligible if they are optional on the part of the payer. If the customer is required to select a tip amount but does not have the option to choose to not tip at all, the minimum possible tip amount is not eligible but any tips exceeding that minimum are eligible.
==== Cosmetic surgery ==== Content promoting cosmetic surgery is popular on TikTok and has spawned several viral trends on the platform. In December 2021, Plastic and Reconstructive Surgery, the journal of the American Society of Plastic Surgeons, published an article about the popularity of some plastic surgeons on TikTok. In the article, it was noted that plastic surgeons were some of the earliest adopters of social media in the medical field and many had been recognized as influencers on the platform. The article published stats about the most popular plastic surgeons on TikTok up to February 2021 and at the time, five different plastic surgeons had surpassed 1 million followers on the platform. In 2021, it was reported that a trend known as the #NoseJobCheck trend was going viral on TikTok. TikTok content creators used a specific audio on their videos while showing how their noses looked before and after having their rhinoplasty surgeries. By January 2021, the hashtag #nosejob had accumulated 1.6 billion views, #nosejobcheck had accumulated 1 billion views, and the audio used in the #NoseJobCheck trend had been used in 120,000 videos. In 2020, Charli D'Amelio, the most-followed person on TikTok at the time, also made a #NoseJobCheck video to show the results of her surgery to repair a broken nose. In April 2022, NBC News reported that surgeons were giving influencers on the platform discounted or free cosmetic surgeries in order to advertise the procedures to their audiences.
=== Category:EC 1.13 (act on single donors with incorporation of molecular oxygen) === Category:EC 1.13.11 (With incorporation of two atoms of oxygen) 4-hydroxyphenylpyruvate dioxygenase (EC 1.13.11.27) Category:EC 1.13.12 (With incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)) Renilla-luciferin 2-monooxygenase EC 1.13.12.5 Cypridina-luciferin 2-monooxygenase EC 1.13.12.6 Firefly luciferase EC 1.13.12.7 Watasenia-luciferin 2-monooxygenase EC 1.13.12.8 Oplophorus-luciferin 2-monooxygenase EC 1.13.12.13
Many of Pauling's critics, including scientists who appreciated the contributions that he had made in chemistry, disagreed with his political positions and saw him as a naïve spokesman for Soviet communism. In 1960, he was ordered to appear before the Senate Internal Security Subcommittee, which termed him "the number one scientific name in virtually every major activity of the Communist peace offensive in this country". A headline in Life magazine characterized his 1962 Nobel Prize as "A Weird Insult from Norway". Pauling was a frequent target of the National Review magazine. In an article entitled "The Collaborators" in the magazine's July 17, 1962, issue, Pauling was referred to not only as a collaborator, but as a "fellow traveler" of proponents of Soviet-style communism. In 1963, Pauling sued the magazine, its publisher William Rusher, and its editor William F. Buckley, Jr for $1 million. He lost both his libel suits and the 1968 appeal (unlike his earlier 1963 libel case against the Hearst Corporation), because in the meantime the landmark case New York Times Co. v. Sullivan had established the actual malice standard for libel lawsuits by public figures, requiring that not only falsehood but deliberate lying should be proved by the plaintiff in such cases. His peace activism, his frequent travels, and his enthusiastic expansion into chemical-biomedical research all aroused opposition at Caltech. In 1958, the Caltech Board of Trustees demanded that Pauling step down as chairman of the Chemistry and Chemical Engineering Division.
Sources: en.wikipedia.org
== Appearance and anatomy == This species can reach a length of 8.8 centimetres (3.5 in) TL. Male dwarf gouramis in the wild have diagonal stripes of alternating blue and red colors; females are a silvery color. Besides the difference in color, the sex can be determined by the dorsal fin. The male's dorsal fin is pointed, while the female's is rounded or curved. They carry touch-sensitive cells on their thread-like pelvic fins. Dwarf gouramis sold in fish stores may also be solid colors (e.g., powder blue dwarf gourami or red flame variety) which are nothing but captive bred color morphs of the same species. Similar to the archerfish, the dwarf gourami can project a stream of water from its mouth to hunt prey above the surface, to a maximum distance of ~5 cm.
{\displaystyle {\begin{array}{lll}M({\ce {He}})&=4.002602(2)\times M_{\mathrm {u} }&=4.002602(2){\text{ g/mol}}\\M({\ce {Ne}})&=20.1797(6)\times M_{\mathrm {u} }&=20.1797(6){\text{ g/mol}}\\M({\ce {Fe}})&=55.845(2)\times M_{\mathrm {u} }&=55.845(2){\text{ g/mol}}\\M({\ce {Cu}})&=63.546(3)\times M_{\mathrm {u} }&=63.546(3){\text{ g/mol}}\\M({\ce {Ag}})&=107.8682(2)\times M_{\mathrm {u} }&=107.8682(2){\text{ g/mol}}\end{array}}}
== Function == S100B is glial-specific and is expressed primarily by astrocytes, but not all astrocytes express S100B. It has been shown that S100B is only expressed by a subtype of mature astrocytes that ensheath blood vessels and by NG2-expressing cells. This protein may function in neurite extension, proliferation of melanoma cells, stimulation of Ca2+ fluxes, inhibition of PKC-mediated phosphorylation, astrocytosis and axonal proliferation, and inhibition of microtubule assembly. In the developing CNS it acts as a neurotrophic factor and neuronal survival protein. In the adult organism it is usually elevated due to nervous system damage, which makes it a potential clinical marker.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.